January 6th to 8th, 2022, Yuan Yuan, head of commerce and business development, GAO Guang, senior technical officer, and DONG Haiyan, senior project officer of Shanghai Representative Office, PATH, visited WestVac BioPharma Co., Ltd. (hereinafter referred to as "WestVac Biopharma"), carried out a three-day investigation and training work, and the WestVac Biopharma team accompanied the investigation and held discussion exchange.
In the course of the exchange, Academician Wei Yuquan, Chairman of WestVac Biopharma, made a detailed introduction to PATH experts on the innovative vaccine R＆D progress, production and quality system construction, talent development and reserves, etc., and pointed out that WestVac Biopharma was focusing on promoting the R＆D and marketing of the first and second generation recombinant COVID-19 vaccines, hoped to receive guidance and support from international organizations such as PATH to accelerate the development of WestVac Biopharma into an international advanced biopharma and provide high-quality vaccine products in the global fight against COVID-19 virus, especially to make WestVac Biopharma's contribution to the realization of the popularization of COVID-19 vaccine for WHO low- and middle-income countries.
Upon fully understanding the basic situation of WestVac Biopharma, PATH experts showed strong interest in the innovative technology and future application of recombinant protein COVID-19 vaccines and novel adjuvants. PATH experts carefully sorted out the relevant content, focusing on the issues such as vaccine process validation, quality control, and application process and on-site inspection of the Emergency Use List (EUL) of World Health Organization (WHO) that WestVac Biopharma focused on, made professional answers to key issues and proposed corresponding optimization measures.
Furthermore, the PATH expert team also came to WestVac Biopharma's vaccine production workshop and QC laboratory to provide on-site guidance and training on stock solution process, preparation production, sterility assurance, quality guarantee, etc. After three days of in-depth exchanges, both parties expressed great expectations for further discussions and cooperation in the future.